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The cystic fibrosis transmembrane conductance regulator (CFTR) has been extensively characterized as the carrier of the basic defect in cystic 
fibrosis. CFTR is part of a growing family of proteins encoded by a single gene, the variant isoforms of which are generated by alternative splicing 
or RNA editing. We have analyzed the CFTR mRNA in the region of exons 10-l 1 in T&l cells and detected an alternatively spliced exon (lob) 
accounting for about 5% of the CFTR mRNA. The exon lob found in both the human and mice genomes, introduces an in-frame stop codon. 
The resulting mRNA is translated into a truncated CFTR protein, identified in T84 cells by immunoprecipitation with the CFTR-specific 
monoclonal antibody MATG 1061. The insertion of a differentially spliced exon carrying an in-frame stop codon is a novel cellular mechanism 
for the production of a protein sharing common sequences with another, but having different properties and functions. 
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1. INTRODUCTION 
The gene coding for the cystic fibrosis transmem- 
brane regulator (CFTR) has been identified as the car- 
rier of the basic defect on cystic fibrosis [l-4]. The func- 
tion of this gene is not yet completely clear although 
most of the evidence indicates CFTR as a protein in- 
volved in the transport of electrolytes, particularly in 
the et&x of chloride ions across the cell membrane 
[5--71. The overall structure of the CFTR (see top draw- 
ing in Fig. 1) consists of two hydrophobic transmem- 
brane domains followed by two nucleotide binding sites 
and a regulatory domain [2,8]. 
CFTR has been extensively characterized, but little 
attention has been given to the fact that its sequences 
are not only found in a unique mRNA but also in some 
variants: one results from the deletion of exon 9 by 
pre-mRNA alternative splicing [lo]; another, from the 
insertion of an extra 260 bp between exons 23 and 24, 
which shortens the intracytoplasmic arboxy-terminus 
[ll]. It has previously been reported that some CFTR 
cDNAs obtained from T84 cells contained ‘aberrant 
sequences’, one of them between exons 10 and 11 [Z]. 
Furthermore PCR analysis of the region spanning 
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T84 (ATCC CCL248) colon carcinoma cell line was plated and 
grown to confluency in MEM supplemented with 5% FBS, in the 
presence of 2 mM glutamine and 50 &ml gentamycin (Gibco/BRL). 
2.2. Oligonucleotide primers 
Abbreviation: CFTR, cystic fibrosis transmembrane conductance reg- We used the following primers for human (h) and mouse (m) se- 
ulator. quences: hl5’ (exon 1, 5’ TAGTAGGTCTTTGGCATTAG 3’); h85’ 
exons 10 and 11 frequently showed extra bands which 
usually have been considered as artifacts 191. This con- 
siderable variation in the structure of mRNA has not 
yet resulted in the identification of variant CFTR pro- 
teins. However, there are several published reports in 
which there is evidence of their existence: in fact, anti- 
CFTR polyclonal antibodies can detect several protein 
bands in Western blots of T84 cell extracts [12]. These 
bands come from a specific anybody-antigen interac- 
tion as they can be competed off by the peptide used to 
produce the antibody. The CFTR proteins are then part 
of a more complex system than previously envisaged, 
resembling the ever growing family of proteins encoded 
by a single gene the alternative splicing of which gener- 
ates variant isoforms which may modulate critical func- 
tions [13-151. We describe here a thorough analysis of 
the region between exons 10 and 11 and identify both 
in human and mouse an alternatively spliced exon that 
results in a drastically altered version of CFTR (CFTR 
36, Fig. 1, bottom drawing) which can be detected in 
T84 cells by i~unoprecipitation. 
2. MATERIALS AND METHODS 
2.1, Cell cuiture 
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(exon 85’ GAAGTAGTGAT~AGAATGT 33; h85’bis (exon 8,5 
GGAATATAAC~AA~GA~ACA 3’); hCl6B (exon 10, 5 
GTITTCCTGGATTATGCCTGGCAC 33; hCl6D (exon 10, 5 
GTTGGCATGCTTTGATGACGCTTC 3’); hlOb5’ (exon lob, 5 
ACTTGGAACTGGAGATG 33; hlOb3’ (exon lob, 5’ TGCCT- 
GCTCCTATGACACTGA 3’); hlObmid (exon lob, 5’ CACTT- 
GCGTATGTAATGATG 3’); hl13’ (exon 11, 5’ TTCTT- 
GCTCGTTGACCTCCA 3’); h133’ (exon 13, 5’ GTTAGCCAT- 
CAGTTTACAGA 3’); mlOb33’ (exon lob, 5’ AAATCACAAG- 
CATGAGGA 3’); mlOb5’int (exon lob, 5’ TGTTCAACTCCGA- 
GATCT 3’). 
[35S]me~ion~e (l~~C~rn1) in methionine-fry medium, washed with 
phosphate-buffered saline and lysed. Lysed cells were divided in two 
aliquots and incubated either with MATG 1061 or OKT4 antibody 
as ascites fluid at 1:lOO final dilution. Staphylococcus aureus (Calbio- 
them) was added for immunoprecipitation and washed with RIPA 
buffer. Pellets were resuspended insample buffer, incubated for 10 min 
at 37”C, subjected to SDS-PAGE, fluorography and autoradiogra- 
phy. 
3. RESULTS AND DISCUSSION 
2.3. RNA extraction, cDNA synt~es~ and PCR ~p~l~cat~on 3.1. ~den~l~ca~i~~ of the exon Mb in bran and mouse 
Total RNA was extracted from 1 x 10’ T84 cells using the guanidin- 
ium thiocyanate lysis method [IQ cDNA was synthesized using a 
specific primer (h133’), mapping into exon 13 of the CFTR sequence. 
At the end of the reaction, the enzyme was heat-inactivated for 10 min 
at 95°C and l/l0 of the transcription reaction was subsequently used 
for PCR amplification, in the presence of 1 PM of each primer, 200 
PM each dNTP, 1.5 mM MgCl, and 2.5 U Tag polymerase (Perkin- 
Elmer-Cetus), in a Perkin-Elmer thermal cycler 480. The amplification 
was obtained after 40 cycles consisting of 60 s at 93”C, 60 s at 56°C 
and 60 s at 72OC. The final product was analysed by electophoresis 
in 1% agarose gel. The fragments produced by PCR were repaired by 
DNA polymerase-Klenow treatment, phosphorylated and purified by 
low-melting agarose electrophoresis. The purified fragment was 
cloned into the SnaaI site of pUCl8, and its sequence determined 
according to standard protocols [16]. 
CFTR genes 
2.4. Genomic clones 
Two lambda clones @XT1 and 1XT2) isolated from a mouse 
genomic library, containing exon 10 and the majority of the intron 
between exons 10 and 11, were a kind gift from Dr. P. Scambler [17]. 
DNA was extracted, digested and fractionated according to standard 
protocols [16]. Southern blot was performed using the cloned human 
exon lob as a probe. 
2.5. Expression of CFTR 36 in T84 cells 
The following monoclonal antibodies were utilized. Mouse anti- 
human CFTR (IgG& raised against amino acids 503-515 of CFTR 
(MATG 1061) which recognizes the first half of the nucleotide binding 
domain 1 [18], was a generous gift from Dr. A. Pavirani (Transgene, 
Strasbourg, France). Mouse anti CD4 antigen OKT4, (IgG& was 
from ATCC and was used as irrelevant antibody. CFTR was labeled 
and immunoprecipitated according to standard methods 1191. Briefly, 
T84 ceils grown in T25 flasks were incubated overnight with 
CFTR mRNA extracted from T84 cells, was used as 
template for cDNA synthesis. The cDNA region span- 
ning exons 8-13 was then subjected to PCR using suita- 
ble primers; the resulting amplified fragments were ana- 
lyzed in agarose gel. Fig. 2A shows the agarose gel 
electrophoresis analysis of the PCR products. It can be 
seen that using T84 cell-derived cDNA and primers 85 
bis and 113, two bands are obtained; they were both 
positive to hybridization with the oligonucleotide 
hC16B present in exon 10. Subsequent cloning and se- 
quencing showed that the bottom band was 517 bp long 
and has the published CFTR sequence (exons 8-l 1) [2] 
while the upper band was 636 bp long and contained an 
alternatively spliced exon (named lob) between exons 
10 and 11. While this manuscript was in preparation 
similar data was reported by Will et al. [23]. The exon 
lob sequence introduces an in-frame stop codon, so that 
the mRNA processed this way would be translated in 
a CFTR protein, truncated at the level of the first nucle- 
otide binding fold (see Fig. 1, bottom drawing). 
To make sure that exon lob belongs to a CFTR 
mRNA in which the frame is not modified by other 
possible alternative splicings, we amplified, cloned and 
sequenced the region from the initial ATG in exon 1 to 
the end of exon lob, using primers h15’ and hlOb3’ for 
the amplification. The clones produced have the normal 
Transmembrane Nucleotide bmdmg R domain Transmembrane Nucleotide bindmg 
domains fold I domains fold II 
t2345 6 7 8 9 10 1112 13 14 15 16 17 18 19 20 21 22 23 24 
- 
CFTA 36 
Fig. 1. Schematic representation of the CFTR structure. CFTR 100 protein is shown in the top drawing. It consists of two transmembrane domains, 
two nucleotide-binding folds and a regulatory domain R. CFTR 36 protein is shown in the bottom drawing. It retains only one transmembrane 
domain and part of the first nucleotide binding fold. Between the two structures, the exons represented in the CFTR mRNA are shown on a 
semi-quantitative scale. 
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Fig. 2. (A) Gel electrophoresis of CFTR PCR fragments. PCR prod- 
ucts obtained using primers hl13’ and h85’bbis: tbe concomitant pres- 
ence of lOb+ and lob- forms in CFTR cDNA, reverse transcribed 
from T84 cells is evident. (B) Autoradiograph of a Southern blot of 
ilXT1 digests. Lanes 1, 2, 3 and 4 show respectively the EcoRI, Hind 
III, SalI and Hinfl digests of ilXT1. The digests were fractionated in 
1.2% agarose gels for 30 min, transferred to nitrocellulose membranes 
and hybrid&d with a clone carrying the human lob exon 3zP-labelled. 
The running conditions of the gel produced a compression of the 
higher molecular weight bands. 
CFTR sequence from exon 1 to 10 followed by the 10b 
exon sequence (see Fig. 3). The nucleotide sequence of 
exon lob was identical both when it was amplified from 
human T84 and other sources such as leukocyte mRNA 
and from human genomic DNA directly. This rules out 
the introduction of the stop codon by RNA editing 
mechanisms as observed in the apolipoprotein B system 
[20]. To confirm the presence of exon lob within the 
CFTR gene we have analyzed mouse CFTR genomic 
clones derived from a region surrounding exon 10 [17]. 
The new exon lob was shown to be present also in the 
mouse genome, mapping 3’ from exon 10. Fig. 3 shows 
the result of a Southern blot performed on aXT1: DNA 
in lanes one to four was digested respectively with 
EcoRI, ElindIII, S&I and HinfI and the probe used was 
the cloned human lob exon sequence. The results show 
that exon lob is entirely contained in a 0.4 kb HinfI 
fragment. Sequence analysis showed that mouse exon 
10b was 74% homologous to the human and presented 
an in-frame stop codon that would produce a truncated 
mouse CFTR, with 25 extra amino acids (see Fig. 3). 
The presence of the in-frame stop codon both in mouse 
and human exonlOb and the 74% nucleotide sequence 
homology (Fig. 3) lend support to the status of coding 
sequence of exon lob. 
3.2. CFTR 36 expression in TM cells 
The confi~ation that a CFTR mRNA containing 
exon lob was biologically active was obtained by the 
detection of the corresponding protein by specific im- 
munopre~ipitation. T84 ceils were metabohcally la- 
belled and the products of the subsequent immunopre- 
cipitation with the CFTR specific antibody MATG 
1061 are shown in Fig. 4, lane 1. Two major bands 
indicated as CFTR 100 and CFTR 36 (named this way 
by analogy with the ApoBlOO/ApoB 48 system [20]) are 
clearly visible. These bands are absent when the irrele- 
vant antibody 0KT4 is used (see Fig. 4, lane 2). CFTR 
36 had an apparent MW of 61 f 1 kDa (n = 3), which 
ctcagtgtgctgcatcaagGCTTGGAATCAGAGAGATGGGGATGGGATATCCTCTTCCTCATGCTTGTGATTTTGTTCAACTCCG 
: : ::::: : : :::: : : : :::: : : :::::::: : : ::: : : ::::::::::: : 
ACTTGGAACTGGAGA31GBGAACAGAATATTATTATCTTCCTCATTTTTGTGTTTTTGTTCAACTCTA 
AGATCTTCAAAGTCCCCTGTGTGTCGmTGCT--- CAGTGTCACAGGAGAATGTGAGTgtggaagggcaagcaatgcacaac 
. . . . . ..* . . . . . . . . . . . . . 
lOtlOb 
SYDEYRYKSWKACQLQQAWQRWGWDILFLMLVILFNSEIFKVPCVS~ 
:::: : :: ::::: :: : 
SYDETRTRSVIKACQLEETWNW~ 
Fig. 3. (A) Comparison between mouse (upper line) and human (bottom line) exon lob sequences (capital etters). Small letters correspond to the 
mouse intronic regions. The mouse junctions are deduced by homology with the human sequence. The dots indicate the homologies between the 
two sequences. In-frame stop codons are underlined. (B) Comparison between the last predicted amino acids of CFTR 36 protein in mouse (top 
line) and man (bottom line). The exon IO-lob boundary derived from the human cDNA sequence is represented by a vertical line, the stops are 
underlined. 
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Fig. 4. Gel electrophoresis ofthe products obtained by immunoprecip- 
itation of T84 cell proteins after labelling with [35S]methionine. Lane 
1 shows the immunoprecipitation products obtained using the CFTR 
specific MATG 1061 antibody. Lane 2 shows the result obtained with 
the irrelevant antibody OKT4. 
is in strict agreement with the predicted mass of 62 kDa 
deduced from the cDNA sequence. The CFTR36/ 
CFTRlOO ratio is higher than expected from their re- 
spective mRNAs abundance (see Fig. 2A, lane 1). This 
may reflect a different immunoprecipitation efficiency 
for both proteins, or a different stability of the respec- 
tive mRNAs. 
At the moment we can only speculate about the pos- 
sible function of the truncated protein CFTR 36. Its 
most interesting structural feature will be the absence of 
the R domain (see Fig. 1, bottom panel), the critical 
regulatory sequence containing most but not all of the 
CFTR 100 protein kinase A substrate sites. The interac- 
tion between the transmembrane domains to form the 
ion channel may be intermolecular instead of being in- 
tramolecular as proposed for CFTR 100 [21]. CFTR 36 
and/or other CFTR related proteins generated from the 
CFTR pre mRNA by alternative splicing could be a 
logical and plausible explanation for some of the incon- 
sistencies reported between the CFTR 100 function, a 
low conductance chloride channel with a linear current- 
voltage relationship, and the actual chloride transport 
deficiencies observed in CF patients whose regulation 
is defective [22]. CFTR alternative splicing variants 
such as CFTR 36 should also be taken into account in 
the functional implications of mutations preceeding 
exon 11 and in any design for gene therapy. A gene 
replacement involving only the major cDNA sequence 
may not provide all the CFTR functions. 
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